Benzinga - by Lisa Levin, Benzinga Editor.
During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high dividend payout.
Benzinga readers can review the latest analyst takes on their favorite stocks by visiting our Analyst Stock Ratings page. Traders can sort through Benzinga's extensive database of analyst ratings, including by analyst accuracy. Here's a look at the most recent high-yield dividend stock ratings from the most accurate Wall Street analysts, according to Benzinga's Analyst Stock Ratings.
Below are the ratings of the most accurate analysts for three high-yielding stocks in the health care sector.
Amgen Inc. (NASDAQ: AMGN)
- Dividend Yield: 3.28%
- Jefferies analyst Michael Yee maintained a Buy rating and boosted the price target from $275 to $310 on Aug. 14, 2023. This analyst has an accuracy rate of 73%.
- Oppenheimer analyst Jay Olson reiterated an Outperform rating with a price target of $280 on July 25, 2023. This analyst has an accuracy rate of 76%.
- Recent News: The U.S. Federal Trade Commission (FTC) has approved drug manufacturer Amgen to proceed with its $27.8 billion acquisition of Horizon Therapeutics Plc (NASDAQ: HZNP).
Medtronic plc (NYSE: MDT)
- Dividend Yield: 3.39%
- Mizuho analyst Anthony Petrone maintained a Buy rating and raised the price target from $95 to $100 on Aug. 23, 2023. This analyst has an accuracy rate of 75%.
- Wells Fargo analyst Larry Biegelsen maintained an Overweight rating and increased the price target from $100 to $102 on Aug. 23, 2023. This analyst has an accuracy rate of 77%.
- Recent News: Medtronic reported the FDA CSDP voted recommending against the approval of Medtronic's blood pressure treatment device, saying associated do not outweigh the benefits.
- Dividend Yield: 3.52%
- Raymond James analyst John Ransom maintained an Outperform rating and cut the price target from $90 to $85 on Aug. 4, 2023. This analyst has an accuracy rate of 75%.
- Truist Securities analyst David Macdonald maintained a Buy rating and cut the price target from $103 to $98 on Aug. 3, 2023. This analyst has an accuracy rate of 78%.
- Recent News: The FDA has issued warning letters to eight companies, including CVS Health, for manufacturing or marketing unapproved ophthalmic drug products violating federal law.
© 2023 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.